Skip Navigation LinksHome > January 2, 2014 - Volume 28 - Issue 1 > Interactions of tenofovir and tenofovir disoproxil fumarate...
AIDS:
doi: 10.1097/QAD.0000000000000112
Basic Science

Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta

Neumanova, Zuzana; Cerveny, Lukas; Ceckova, Martina; Staud, Frantisek

Free Access
Article Outline
Collapse Box

Author Information

Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.

Correspondence to Professor, PharmDr, Frantisek Staud, Ph.D., Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic. Tel: +420 495 067 407; fax: +420 495 067 170; e-mail: frantisek.staud@faf.cuni.cz

Received 14 August, 2013

Revised 08 October, 2013

Accepted 08 October, 2013

Collapse Box

Abstract

Objective and design: Tenofovir (TFV) is used in pregnant women as a part of combination antiretroviral treatment to prevent mother-to-child transmission of HIV infection. We aimed to detect whether TFV and/or its prodrug, tenofovir disoproxil fumarate (TDF), are substrates of ATP-binding cassette (ABC) transporters that are functionally expressed in the placenta, namely P-glycoprotein (ABCB1/MDR1), Breast Cancer Resistance Protein (ABCG2/BCRP) and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2). We employed in-vitro cell-based assays and in-situ animal model to assess possible role of the efflux transporters in transplacental pharmacokinetics of TFV and TDF.

Methods: In-vitro transport assays were performed in MDCKII cells transduced with human ABCB1, ABCG2 or ABCC2. To quantify the effect of these transporters on TFV/TDF transplacental passage, we employed the in-situ model of dually perfused rat term placenta in open and closed setup.

Results: In-vitro assays revealed that TDF is a dual substrate of ABCB1 and ABCG2 but not of ABCC2. In contrast, TFV transport was not influenced by any of these transporters. Applying concentration-dependent studies and selective inhibitors, we further confirmed these findings in situ on the organ level; both ABCB1 and ABCG2 limited mother-to-fetus transfer of TDF whereas TFV transplacental passage was not affected by these ABC transporters.

Conclusion: We propose limited mother-to-fetus transport of both TFV and TDF. While placental transport of TFV is restricted passively, by physical-chemical properties of the molecule, mother-to-fetus passage of TDF is actively hindered by placental ABCB1 and ABCG2 transporters, pumping this compound from trophoblast back to maternal circulation.

Back to Top | Article Outline

Introduction

An estimated 1.5 million pregnant women were living with HIV in 2011 [1]. According to the WHO, all infected women, regardless of their clinical stage, should receive combination antiretroviral treatment throughout gestation to prevent HIV mother-to-child transmission (MTCT) [2]. Together with other evidence-based interventions, antiretroviral pharmacotherapy in pregnancy reduces the percentage of HIV-positive infants from 20–45% to 1–2% [3].

Tenofovir (TFV), a nucleotide reverse transcriptase inhibitor, represents a backbone of combination anti-HIV therapy [4]. To improve its pharmacokinetic properties, TFV is administered in the form of disoproxil fumarate. Despite being classified as pregnancy category B drug, WHO has incorporated tenofovir disoproxil fumarate (TDF) into recent guidelines for prophylaxis of HIV MTCT [2] and its use in pregnancy tends to increase [5,6]. It must be stressed out that medication of pregnant women requires special attention to guarantee adequate and well tolerated therapy throughout gestation; among others, changes in pharmacokinetics during pregnancy [7] and quantification of drug transport across the placenta [8] need to be taken into account.

Several members of ATP-binding cassette (ABC) drug efflux transporters have been localized in the apical, maternal-facing membrane of the placenta where they pump their substrates from the trophoblast cells back to the maternal circulation, thus limiting permeation of substrate drugs from mother to fetus [8]. To date, the best-described ABC transporters in the placenta are: P-glycoprotein (ABCB1/MDR1) [9], Breast Cancer Resistance Protein (ABCG2/BCRP) [10] and Multidrug Resistance-Associated Protein 2 (ABCC2/MRP2) [11]. It has been well documented that these transporters affect transplacental passage of many clinically used compounds, including antiretrovirals [12]. Therefore, detailed knowledge on drug interactions with placental ABC transporters is required to complete their safety profile and to guarantee adequate and well tolerated medication of pregnant woman and her child [13]. Interactions of TFV and TDF with ABCB1 and ABCC2 have been investigated in several studies, however, providing inconsistent results depending on the method used [14–20]. To our knowledge, data clearly describing ABCG2-mediated transport of TFV or TDF is still lacking. In addition, influence of ABC transporters on transplacental passage of these compounds has not been evaluated so far.

In the present study, we employed the in-vitro model of MDCKII cells transduced with human ABC transporters to investigate whether TFV and/or TDF are substrates of human ABCB1, ABCG2 or ABCC2. Furthermore, using the model of in-situ perfused rat placenta we aimed to elucidate potential effect of these transporters on TFV/TDF passage from mother to fetus.

Back to Top | Article Outline

Methods

Reagents and chemicals

Tenofovir [TFV, (1R)-9-(2-Phosphonylmethoxypropyl)-adenine)] and tenofovir disoproxil fumarate [TDF; bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)-adenine] were kindly provided by Gilead Sciences, Inc. (Foster City, California, USA). Radiolabeled [adenine-2,8–3H]tenofovir ([3H]TFV) and [adenine-8–3H] tenofovir disoproxil fumarate ([3H]TDF) were purchased from Moravek Biochemicals (California, USA). Dual ABCG2 and ABCB1 inhibitor, GF120918, was kindly provided by GlaxoSmithKline (Greenford, UK). Indomethacin, nonselective inhibitor of ABCC(s), was purchased from Sigma–Aldrich (St. Louis, Missouri, USA). Pentobarbital (Nembutal) was purchased from Abbott Laboratories (Abbott Park, Illinois, USA). All other chemicals were of analytical grade.

Back to Top | Article Outline
Cells

MDCKII (Madine-Darby Canine Kidney) parental cell line and MDCKII cells stably transduced with cDNA of human MDR1 (MDCKII-ABCB1), BCRP (MDCKII-ABCG2) or MRP2 (MDCKII-ABCC2) were obtained from Netherlands Cancer Institute (Dr A. Schinkel) and cultured in DMEM complete high-glucose medium with L-glutamine, supplemented with 10% fetal bovine serum.

Back to Top | Article Outline
Animals

Pregnant Wistar rats were purchased from Biotest Ltd. (Konarovice, Czech Republic) and were maintained in 12/12-h day/night standard conditions with water and pellets ad libitum. Experiments were performed on day 21 of gestation. Fasted rats were anesthetized with pentobarbital (Nembutal; Abbott Laboratories) in a dose of 40 mg/kg administered into the tail vein. All animal experiments were approved by the Ethical Committee of the Faculty of Pharmacy in Hradec Kralove (Charles University in Prague, Czech Republic) and were carried out in accordance with the Guide for the Care and Use of Laboratory Animals (1996) and the European Convention for the Protection of Vertebrate Animals used for experimental and other scientific purposes.

Back to Top | Article Outline
Transport experiments in vitro

Transport assays were performed on microporous polycarbonate membrane filters (3.0 μm pore size, 24 mm diameter; Transwell 3414; Costar, Corning, New York, New York, USA) as described previously [21]. MDCKII-parental and MDCKII cells expressing ABCB1, ABCG2 or ABCC2 were seeded at a density of 1.0 × 106 cells per well and cultured for 72 h to confluence, including daily medium replacement. One hour before starting the experiment, cells were washed with phosphate-buffered saline (37°C) and incubated with 2 ml of Opti-MEM (Invitrogen, Carslbad, California, USA) either alone or containing the dual ABCB1 and ABCG2 inhibitor GF120918 (2 μmol/l). The experiment was started by replacing the medium in the donor compartment (either apical or basolateral) with fresh Opti-MEM (37°C) containing the tested compound, TFV or TDF, or combination of TDF with GF120918 (2 μmol/l). Both TFV and TDF were traced by [3H]TFV and [3H]TDF, respectively, achieving the final activity of 0.04 μCi/ml. The lowest point of the concentration range (3.1 nmol/l for TFV and 33.3 nmol/l for TDF) was determined by the specific activity of radioisotopes required for analysis. Aliquots of 50 μl were collected at 2, 4 and 6 h from the acceptor compartment and radioactivity was measured by liquid scintillation counting (Tri-Carb 2900 TR Perkin Elmer). At the end of the experiment leakage of FITC-dextran was analysed and was accepted up to 1% per hour. The percentage of radioactivity appearing in the acceptor compartment relative to stock solution initially added to the donor compartment was calculated. Ratios of basal-to-apical to apical-to-basal translocation after 6-h incubation (r) were calculated as described elsewhere [21,22].

Back to Top | Article Outline
Dual perfusion of the rat placenta in situ

The method of dually perfused rat term placenta was used as described previously [23]. In brief, one uterine horn was excised and submerged in heated Ringer's saline. A catheter was inserted into the uterine artery proximal to the blood vessel supplying a selected placenta and connected with the peristaltic pump. Kreb's perfusion liquid containing 1% dextran was brought from the maternal reservoir at a rate 1 ml/min. The uterine vein, including anastomoses to other fetuses, was ligated behind the perfused placenta and cut so that maternal solution could leave the perfused placenta. The selected fetus was separated from the neighbouring ones by ligatures. The umbilical artery was catheterized by use of a 24-gauge catheter connected to the fetal reservoir and perfused at a rate of 0.5 ml/min. The umbilical vein was catheterized in a similar manner, and the selected fetus was removed. Before the start of each experiment, the fetal vein effluent was collected into preweighed glass vial to check for a possible leakage of perfusion solution from the placenta. In the case of leakage, the experiment was terminated. Maternal and fetal perfusion pressures were maintained at levels close to physiological values and monitored continuously throughout the perfusion experiments as described previously. At the end of experiment, placenta was perfused with radioactivity-free buffer for 10 min, excised from the uterine tissue, and dissolved in tissue solubilizer (Solvable; PerkinElmer Life and Analytical Sciences), and its radioactivity was measured to detect tissue-bound TFV or TDF.

Two types of perfusion systems were used in this study:

Open-circuit perfusion system was employed to study fetal-to-maternal (F > M) and maternal-to-fetal (M > F) clearances of TFV or TDF at various concentrations. TFV (50 nmol/l or 500 μmol/l) and TDF (50 nmol/l, 100 or 500 μmol/l) was added to either maternal (M>F studies) or fetal (F>M studies) reservoir immediately after successful surgery. After 5-min stabilization period the sample collection started (time 0). Fetal effluent was sampled into preweighed vials in 5 min interval, concentrations were measured radiometrically and transplacental clearance was calculated from all measured intervals as described below.

Closed-circuit (recirculation) perfusion system was employed to identify placental transporter(s) responsible for active transport of TDF from the fetal circulation. Both maternal and fetal sides of the placenta were infused with either nonsaturating (50 nmol/l) or saturating (500 μmol/l) concentrations of [3H]TDF and after short-time stabilization period, the fetal perfusate (10 ml) was recirculated for 60 min. Samples (250 μl) were collected every 10 min from the maternal and fetal reservoirs, and concentrations of [3H]TDF were measured. This experimental setup ensures steady concentration on the maternal side of the placenta and enables investigation of fetal/maternal ratio; any net transfer of the substrate implies transport against a concentration gradient and provides evidence of active transport. To determine the effect of efflux transporters on placental passage of TDF, GF120918 (2 μmol/l), a dual inhibitor of ABCB1 and ABCG2 [24], or indomethacin (0.28 mmol/l), a nonspecific inhibitor of ABCCs [25], were added to both maternal and fetal reservoirs and the fetal/maternal concentration ratio at equilibrium was calculated.

Back to Top | Article Outline
Pharmacokinetic analysis of efflux transport activity in the placenta

Organ clearance concept was applied to quantify M > F and F > M transport of TFV and TDF in open-circuit perfusion system [23]. Averaged data from the intervals of 10–35 min were used for the following calculations. M > F transplacental clearance (Clmf) normalized to placenta weight was calculated according to Eq. (1).

Equation (Uncited)
Equation (Uncited)
Image Tools

where Cfv is drug concentration in the umbilical vein effluent, Qf is the umbilical flow rate, Cma is concentration in the maternal reservoir, and Wp is the wet weight of the placenta. F > M transplacental clearance (Clfm) was calculated according to Eq. (2).

Equation (Uncited)
Equation (Uncited)
Image Tools

where Cfa is drug concentration in the fetal reservoir entering the perfused placenta via the umbilical artery.

Back to Top | Article Outline
Statistical analysis

In in-vitro cell-based studies, two-side unpaired Student's t-test was employed to compare apical-to-basal translocation and basal-to-apical-translocation at time point 6 h. In in-situ placenta perfusion studies, statistical significance was examined by two-side unpaired Student's t-test or one-way ANOVA followed by Bonferroni's test. All data were assessed using GraphPad Prism 6.0 software (GraphPad Software, Inc., San Diego, California, USA).

Back to Top | Article Outline

Results

TFV transport across MDCKII parental and ABCB1, ABCG2, ABCC2-overexpressing cells

We first determined transepithelial transport of [3H]TFV at the concentration of 3.1 nmol/l through the monolayers of parental and ABCB1, ABCG2 or ABCC2-overexpressing cells. No asymmetry in basal-to-apical vs. apical-to-basal transport of TFV was observed in MDCKII parental cells (r = 0.90). Transports across MDCKII-ABCB1, ABCG2 and ABCC2 monolayers were equivalent to that in parental cell line (r = 0.89, 0.79 and 0.89, respectively) (Table 1). These findings show that TFV is not a substrate of any of the transporters investigated.

Table 1
Table 1
Image Tools
Back to Top | Article Outline
TDF transport across MDCKII parental and ABCB1, ABCG2, ABCC2-overexpressing cells

Transepithelial transport of [3H]TDF through MDCKII parental and ABCB1, ABCG2, ABCC2-overexpressing cells was measured at a concentration of 33.3 nmol/l. In the parental cells, basal-to-apical/apical-to-basal transport ratio (r) of 2.38 was observed likely resulting from activity of endogenous canine transporters as reported previously [22]. Compared with MDCKII parental cells, significantly larger basal-to-apical/apical-to-basal ratios were observed in ABCB1 and ABCG2-overexpressing cells (r = 5.47 and 6.24, respectively) but not in ABCC2 cells (r = 3.06). Increase in TDF concentration (10 μmol/l) significantly reduced this ratio in both ABCB1 and ABCG2 cells (r = 4.56 and r = 4.78, respectively) indicating partial saturation of both transporters. Furthermore, addition of a dual ABCB1 and ABCG2 inhibitor, GF120918 (2 μmol/l), completely abolished the asymmetry in translocation of TDF in respective cell lines at both concentrations tested (33.3 and 10 μmol/l) reaching transport ratio values of approximately 1. These findings demonstrate that TDF is a substrate of human ABCB1 and ABCG2 but not of ABCC2 (Table 2).

Table 2
Table 2
Image Tools
Back to Top | Article Outline
Open circuit perfusion experiments: effect of inflow concentrations on transplacental clearance of TFV and TDF

The maternal or fetal side of the placenta was infused with various concentration of TFV (50 nmol/l or 500 μmol/l) or TDF (50 nmol/l, 100 or 500 μmol/l). No statistically significant differences between M>F and F>M clearances were observed at either low or high concentration of TFV, suggesting linear mechanism in transplacental transport of this compound. On the contrary, increase in TDF concentration resulted in significant changes in transplacental clearances in both M>F and F>M directions, confirming involvement of a capacity-limited transport mechanisms (Fig. 1). Less than 5% of TFV or TDF dose was detected in the placenta after perfusion experiments, suggesting limited tissue binding and negligible effect on clearance calculation.

Fig. 1
Fig. 1
Image Tools
Back to Top | Article Outline
Closed circuit perfusion experiments: effect of concentration and inhibitors on TDF transport across the placenta

To identify placental transporter(s) responsible for elimination of TDF from the fetal circulation, both sides of placenta were perfused with low nonsaturating concentration of TDF in closed circuit experimental setup in either absence or presence of inhibitors. In the absence of inhibitors, we observed significant decrease in TDF concentration in fetal perfusate, confirming active transport of this compound from fetal to maternal side of the placenta against concentration gradient. This decline was fully blocked by coinfusion with 500 μmol/l TDF confirming saturable transport. Furthermore, transport of TDF from fetus to mother was significantly blocked by GF120908 (2 μmol/l), whereas co-administration of indomethacin (0.28 mmol/l) did not show any effect (Fig. 2).

Fig. 2
Fig. 2
Image Tools
Back to Top | Article Outline

Discussion

Although TFV is categorized as a pregnancy B drug by FDA, it is frequently used in the treatment of pregnant women with HIV infection. Nevertheless, transport of this compound, and its prodrug TDF, across the placenta from mother to fetus and the role of placental ABC drug efflux transporters in this event have not been systematically investigated to date. In this study we employ both in-vitro and in-situ experimental approaches to characterize interactions of TFV and TDF with the best-described ABC transporters localized in the placenta, that is ABCB1, ABCG2 and ABCC2, and to quantify their role in the transplacental pharmacokinetics of both compounds.

Using in-vitro transport experiments in MDCKII cells overexpressing human ABCB1, ABCG2 or ABCC2 we did not record any asymmetry in transepithelial translocation of TFV, indicating this compound is not a substrate of any of these transporters (Table 1). This correlates well with previously published data by Ray et al.[14] who used identical experimental model to exclude interactions between ABCB1 and TFV. We also support recent findings by Cihlar et al.[15] and Rodriguez-Novoa et al.[26] who suggested no role of ABCC2 in TFV pharmacokinetics. In addition, we provide the first evidence that ABCG2 does not mediate TFV transport.

TDF, on the contrary, showed strikingly different behaviour in comparison with TFV. When investigating its transport across ABCB1-transduced cells in basal-to-apical vs. apical-to-basal direction, TDF achieved transport ratio (r) 2–2.6 times higher than that observed in the parental cell line. Furthermore, application of GF120918 (2 μmol/l) abolished this asymmetry, resulting in translocation of TDF across the cell monolayer by mechanism of passive diffusion (r ≈ 1). These findings clearly confirm TDF as a substrate of ABCB1 transporter as suggested recently [17,18]. Based on our findings, TDF seems to be a substrate as strong as colchicine, model substrate often used for in-vitro assays [27], topotecan [22] or other antiretrovirals including zidovudine [28], abacavir [29] or lopinavir [30].

Similarly, in-vitro studies in ABCG2-transduced MDCKII cells revealed that TDF is transported by ABCG2. To our knowledge we provide the first evidence that pharmacokinetics of TDF can be affected by ABCG2 transporter. Conversely, Janneh et al. have recently reported [31] that application of dipyridamole, a nonspecific inhibitor of ABCB1 and ABCG2, resulted in insignificant increase in TDF accumulation within peripheral mononuclear cells suggesting that TDF is not a substrate of ABCG2. However, since their method failed to reveal transport of TDF by ABCB1 either, we speculate that low sensitivity of the experimental approach prevented disclosure of interaction between TDF and both ABC transporters in their study.

To confirm our in-vitro findings on the organ level, we employed the method of dually perfused rat term placenta, a well established method to study placental pharmacology [23,24,32,33] and physiology [34,35]. As both rat and human placenta express abundant amounts of ABCB1 [9] and ABCG2 [10], we introduced this model as a suitable tool to investigate the role of placental ABCB1 [33] and ABCG2 [23] in placental disposition of drugs. In open-circuit perfusion setup, clearances of TFV in both fetal-to-maternal and maternal-to-fetal directions were comparable and independent of drug concentration. These findings indicate linear pharmacokinetics without involvement of transporter-mediated mechanism(s) (Fig. 1) and correspond well with our results obtained in vitro. Furthermore, low values of TFV transplacental clearances suggest its restricted passage across the placenta when compared with antipyrine, a marker of passive diffusion [24]. This is in accordance with observations by Nirogi et al.[36] who found TFV in the placenta but not in amniotic fluid and fetal tissues when administered as a single fixed dose of efavirenz-emtricitabine-TDF in rats. Poor TFV transport was also observed in other biological membranes such as the intestine [37], blood–brain barrier [38] or blood–cerebrospinal barrier [39] most likely due to physical–chemical properties of the molecule, that is its anionic charge at physiological pH and low lipid-solubility of the nonionized fraction. Therefore, it is reasonable to assume that this molecule cannot readily cross cell membranes by passive diffusion; however, involvement of other transporters, such as equilibrative nucleoside transporters and/or concentrative nucleoside transporters, in TFV pharmacokinetics cannot be excluded.

Once absorbed, TDF is cleaved by nonspecific esterases, thus occurring in the systemic circulation predominantly as TFV [40]. However, esterase-mediated degradation of TDF can be inhibited by concomitantly administered treatment or substances normally present in nutrition such as fruit esters [17,18]. It can be hypothesized that TDF, at least to some extent, can also circulate in the maternal blood and reach the placental barrier; therefore, in this study we investigated placental transfer of TDF as well. In contrast to TFV, we observed great asymmetry in TDF transplacental clearances between mother to fetus and fetus to mother. In detail, transport from fetus to mother was 11.7 times faster than that in the opposite direction. In addition, placental transport of this drug was concentration-dependent in both directions indicating involvement of a saturable transport mechanism. Furthermore, employing closed-circuit perfusion setup with low, nonsaturating TDF concentrations, we observed transport of the drug from fetal to maternal circulation against concentration gradient confirming active transport mechanism. This transport was significantly reduced by administration of GF120908, a common ABCG2 and ABCB1 inhibitor, confirming ability of these transporters to mediate passage of TDF from fetus to mother (Fig. 2). Taking these results together with findings from in-vitro transport experiments in MDCKII-transduced cells, we conclude that both ABCB1 and ABCG2 affect TDF transplacental kinetics. On the contrary, indomethacin, a nonspecific inhibitor of ABCC(s), did not affect TDF transplacental transport, indicating that ABCC2 does not modulate transplacental passage of TDF. As drug–drug interactions on ABC transporters may substantially affect the fate of drugs in organism, our findings should be taken into account when TDF is co-administered with compounds whose membrane transport is mediated by ABCB1 and/or ABCG2 such as antiretrovirals [41] or other drugs administered in pregnancy [8]. Differences in ABCB1 expression between HIV-infected and noninfected women [42] as well as genetic polymorphisms leading to altered expression and function of the protein in the placenta [43] should also be considered when substrate drugs are prescribed.

In summary, our cell-based results suggest that TFV does not interact with human ABCB1, ABCG2 or ABCC2 transporters, whereas TDF was shown to be a dual substrate of both ABCB1 and ABCG2 but not of ABCC2. Our in-situ experiments in perfused rat placenta confirmed these findings, suggesting that ABCB1 and ABCG2, but not ABCC2, play an important role in efflux of TDF from fetus to mother. We propose limited mother-to-fetus transport of both TFV and TDF. While placental transport of TFV is restricted passively, by physical–chemical properties of the molecule, limited mother-to-fetus passage of TDF is actively mediated by placental ABCB1 and ABCG2 transporters, pumping this compound from trophoblast back to maternal circulation.

Back to Top | Article Outline

Acknowledgements

Z.N. performed in-situ placenta perfusion experiments, analysed the data and participated in writing the manuscript; L.C. designed and performed in-vitro cell-based experiments, analysed the data and participated in writing the manuscript; M.C. cultivated the cells, designed and performed in-vitro cell-based experiments and critically revised the article; F.S. designed and supervised the experiments, analysed the data and participated in writing the article.

This research was financially supported by Czech Science Foundation (GACR P303/120850) and Grant Agency of Charles University (GAUK 695912/C/2012 and SVV/2013/267-003). We thank Gilead Sciences, Inc. (333 Lakeside Drive Foster City, California 94404, USA) for providing TFV and TDF. We also wish to thank Dana Souckova and Renata Exnarova for skilful assistance with the perfusion experiments.

Back to Top | Article Outline
Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References

1. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards Universal Access Progress report 2011 (WHO, UNAIDS, UNICEF) http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf. [Accessed on 13 June 2013].

2. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommendations for a public health approach (2010 version) http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf. [Accessed on 29 May 2013].

3. Cavarelli M, Scarlatti G. Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies. J Intern Med 2011; 270:561–579.

4. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. [Accessed on 7 April 2013].

5. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009; 23:513–520.

6. Griner R, Williams PL, Read JS, Seage GR 3rd, Crain M, Yogev R, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS 2011; 25:385–394.

7. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab 2009; 10:520–529.

8. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target 2012; 20:736–763.

9. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 2006; 22:400–410.

10. Hahnova-Cygalova L, Ceckova M, Staud F. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev 2011; 43:53–68.

11. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005; 33:896–904.

12. Gulati A, Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J Pharm Sci 2009; 98:2317–2335.

13. Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 2012; 51:639–659.

14. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297–3304.

15. Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007; 12:267–272.

16. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and nonnucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35:340–344.

17. van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30:924–930.

18. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498–3504.

19. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73:1573–1581.

20. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005; 35:1055–1066.

21. Cerveny L, Pavek P, Malakova J, Staud F, Fendrich Z. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. Epilepsia 2006; 47:461–468.

22. Poller B, Wagenaar E, Tang SC, Schinkel AH. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 2011; 8:571–582.

23. Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, et al. Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 2006; 319:53–62.

24. Cygalova LH, Hofman J, Ceckova M, Staud F. Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 2009; 331:1118–1125.

25. Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 2010; 386:216–220.

26. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48:e108–e116.

27. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006; 34:786–792.

28. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci 2009; 98:4413–4419.

29. Shaik N, Giri N, Pan G, Elmquist WF. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 2007; 35:2076–2085.

30. Agarwal S, Pal D, Mitra AK. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 2007; 339:139–147.

31. Janneh O, Bray PG, Jones E, Wyen C, Chiba P, Back DJ, et al. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2011; 65:906–916.

32. Ahmadimoghaddam D, Hofman J, Zemankova L, Nachtigal P, Dolezelova E, Cerveny L, et al. Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat. Toxicol Sci 2012; 128:471–481.

33. Pavek P, Staud F, Fendrich Z, Sklenarova H, Libra A, Novotna M, et al. Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J Pharmacol Exp Ther 2003; 305:1239–1250.

34. Stulc J, Stulcova B, Sibley CP. Mechanisms of the fetomaternal transfer of Na+ across the dually perfused placenta of the rat. Placenta 1995; 16:127–135.

35. Jakoubek V, Bibova J, Herget J, Hampl V. Chronic hypoxia increases fetoplacental vascular resistance and vasoconstrictor reactivity in the rat. Am J Physiol Heart Circ Physiol 2008; 294:H1638–1644.

36. Nirogi R, Bhyrapuneni G, Kandikere V, Muddana N, Saralaya R, Komarneni P, et al. Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and nonpregnant rats. Biopharm Drug Dispos 2012; 33:265–277.

37. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the antihuman immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998; 42:687–690.

38. Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 2006; 3:1.

39. Best BM, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, et al. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 2012; 59:376–381.

40. Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14:1824–1829.

41. Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31:22–35.

42. Camus M, Delomenie C, Didier N, Faye A, Gil S, Dauge MC, et al. Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta 2006; 27:699–706.

43. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GD, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2011; 79:921–925.

Keywords:

breast cancer resistance protein; multidrug resistance-associated protein 2; P-glycoprotein; pregnancy; tenofovir; tenofovir disoproxil fumarate; transplacental pharmacokinetics

© 2014 Lippincott Williams & Wilkins, Inc.

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.